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Abstract
Background: Hemophagocytic lymphohistiocytosis (HLH) is a clinical syndrome with both genetic and acquired
causes characterized by elevated cytokine levels, hyperinflammation, and overactivation of lymphocytes and
macrophages. It is typically a systemic disease with variable degrees of CNS involvement. Cases with predominantly
central nervous system (CNS) involvement are very rare, with the vast majority of these occurring in infants and
young children. This report documents a case of adult-onset CNS-HLH involving a middle-aged man.
Case presentation: A 55 year-old man developed progressive left hemiparesis and aphasia over the course of
several months. Brain MRI showed multifocal, mass-like enhancing lesions with increased susceptibility consistent
with blood products. An extensive workup for infectious, autoimmune, and neoplastic etiologies was significant
only for a markedly elevated serum ferritin at 1456 ng/mL. Two brain biopsies showed a non-specific inflammatory
process. The patient was treated empirically with steroids and plasmapheresis, but he continued to suffer a
progressive neurological decline and died one year after onset of neurological symptoms. Autopsy revealed
profound histiocytic infiltration, perivascular lymphocytosis, and emperipolesis, compatible with CNS-HLH.
Conclusion: This case report describes an exceedingly rare presentation of an adult patient with CNS predominant
HLH. This diagnosis should be considered in the differential diagnosis of adults presenting with progressive brain
lesions, even in the absence of typical systemic signs of HLH.
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Background
Hemophagocytic lymphohistiocytosis (HLH) is a clinical
syndrome characterized by elevated cytokine levels,
hyperinflammation, and overactivation of lymphocytes
and macrophages [1–5]. In infants and young children,
the disease is primarily caused by a genetic mutation in
one of the genes responsible for cytotoxic function of
natural killer cells and cytotoxic T lymphocytes. In older
children, adolescents, and adults, acquired causes pre-
dominate and include infectious, neoplastic, autoinflam-
matory, autoimmune, and immunodeficiency etiologies.
While HLH is more frequently a systemic disease with
variable degrees of central nervous system (CNS) in-
volvement, cases with predominantly CNS involvement
can occur with resulting meningitis, seizures, and optic
neuritis [6–12]. In such cases, the vast majority of pa-
tients are infants and young children. This report docu-
ments a case of adult-onset CNS-HLH involving a
middle-aged man, which is an exceedingly rare presenta-
tion of which physicians should be aware.
Case presentation
A 55 year-old healthy male business owner presented to
a local community hospital after two months of painless
left calf swelling that developed in January 2012. An
ultrasound ruled out deep vein thrombosis, but an MRI
suggested diffuse myositis of his left soleus muscle. Ini-
tially he was treated for cellulitis, but after failing to
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improve with antibiotics, the diagnosis of autoimmune
myositis was entertained. A muscle biopsy showed non-
specific endomysial inflammation, and prednisone was
started. His left calf swelling improved partially over the
next several weeks.
In May 2012 the patient developed disequilibrium and
gait unsteadiness over a period of a few days. This was
followed a week later by a left foot drop, and then two
weeks later by right hand parasthesias. He denied any fe-
vers, weight loss, night sweats, or unusual rashes. He
was referred to a local rheumatologist who, being con-
cerned about the progressive symptoms, admitted him
to our hospital for an expedited workup.
The patient was relatively healthy prior to onset. He
was an avid runner and owned a successful business. In-
triguingly, he had episode of right hand clumsiness in
2003 at age 46 that developed gradually and resolved
slowly over months without clear etiology or any specific
treatment. At the time he was found to have lesions in
his right cerebellum and right frontal lobe with hemosid-
erin deposition deemed to be sub-acute infarcts (Fig. 1).
By 2004, though, he was completely functional with no
symptoms or deficits.
He had a daughter with AML and both a maternal
grandmother and maternal cousin with strokes in their
40s. He was married with two children. Other than the
prednisone that he had started for possible myositis, he
was taking no other medications. He was not allergic to
any medications.
On examination at the time of admission in June 2012,
he was afebrile without rash, lymphadenopathy, or hepa-
tosplenomegaly. He did have left lower extremity swell-
ing. He was alert, fully oriented, with fluent speech and
normal language. He had normal attention (digits
forward of 6), but had poor short-term recall (0/3 at
5 min even with cues). On cranial nerve testing he was
found to have a right facial droop. He had diffuse left
lower extremity weakness that was worse distally in a
pyramidal distribution. His deep tendon reflexes were
brisk on the left compared to the right, and he had a
Babinski response on the left. He had decreased
sensation to pinprick over the right fifth finger. Finger-
to-nose was on-target bilaterally. He had a positive Rom-
berg test, and had a steppage gait on his left.
Labs upon admission revealed unremarkable complete
blood count, chemistry panel, coagulation panel, and
liver function tests. Human immunodeficiency virus
(HIV) antibody was negative, rapid plasma reagin (RPR)
was nonreactive, and hepatitis B and C virus serologies
were negative. Erythrocyte sedimentation rate (ESR) was
6 before starting prednisone in March, and was 3 upon
admission. Anti-nuclear antibody (ANA) titer was
weakly positive at 1:40 and speckled, anti-double
stranded DNA was negative, rheumatoid factor was
negative, complement levels were normal, and both
cytoplasmic and perinuclear anti-neutrophil cytoplasmic
antibodies (c-ANCA and p-ANCA) were negative. Cre-
atine kinase was elevated to 511. Ferritin was very ele-
vated at 1456. A lumbar puncture was performed which
showed 1 white blood cell; 43 red blood cells; protein of
69; glucose of 47 (serum glucose of 122); an immuno-
globulin (Ig) G index of 0.6; and multiple oligoclonal
bands present in both the serum and CSF (Table 1).
Initial MRI brain showed multiple supra- and infraten-
torial areas of mass-like T2 hyperintensity with regional
mass-effect involving cortex and juxtacortical white mat-
ter and increased susceptibility in the largest lesions
consistent with blood products (Fig. 2). There was
Fig. 1 Magnetic resonance images from May 2003. Coronal fluid-attenuated inversion recovery (FLAIR) sequences through the posterior
cerebellum (a) and the frontal lobe (b)
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patchy, predominantly cortical enhancement within
most of the lesions. The radiologic differential diagnosis
at the time was sub-acute infarctions secondary to vas-
culopathy/vasculitis, embolic disease, or hypercoaguabil-
ity; an underlying metabolic or mitochondrial disorder
such as MELAS; a hemorrhagic encephalitis; or less
likely a demyelinating pseudotumor.
Given these MRI findings, a broader laboratory
workup was initiated to look for infectious, autoimmune,
metabolic, paraneoplastic, or neoplastic processes
(Table 2). This was still non-diagnostic, including nor-
mal triglycerides, fibrinogen, natural killer cell function,
and soluble interleukin-2 receptor level. An MRI of the
spine; MRA of the brain; CT of the chest, abdomen, and
pelvis; FDG-PET whole body scan; and a transesopha-
geal echocardiogram were also all unremarkable.
Shortly after admission, the patient suffered a focal
seizure with secondary generalization and was started on
levetiracetam. He declined neurologically throughout
June 2012 with worsening confusion, aphasia, and left-
sided weakness. He developed occasional fevers as high
as 39.9 during this month without ever having a con-
firmed infection.
Two brain biopsies were performed in late June 2012.
The first, from a right parietal lobe lesion, showed a
macrophage-rich process associated with areas of necro-
sis and a mild-moderate chronic inflammatory infiltrate.
The second, from a right temporal lobe lesion, showed a
similar macrophage-rich process involving both the
cerebral cortex and white matter. No evidence of vascu-
litis was present in either specimen. A bone marrow bi-
opsy was also unrevealing.
Despite this extensive workup, no clear diagnosis
could be made. Suspecting an autoimmune process, IV
solumedrol was administered, followed by plasmapher-
esis and a 5-month steroid taper. He was discharged to a
skilled nursing facility in August 2012.
Despite immunosuppression, the patient continued to
decline. By September 2012, he was wheelchair-bound
with spastic quadriparesis, mute, and unable to maintain
proper nutrition by mouth. A percutaneous endoscopic
gastrostomy tube was placed in the fall of 2012. He died
of aspiration pneumonia in the spring of 2013. An aut-
opsy was performed.
Autopsy results
Evaluation of the fresh brain showed multifocal areas of
yellow discoloration and parenchymal softening at the
surface, involving the bilateral frontal lobes, right




Blood urea nitrogen (BUN) 14 mg/dL
Creatinine 0.9 mg/dL
Glucose (non-fasting) 122 mg/dL
White blood cell count 3.7 X 10^9/L
Hemoglobin 13.9 g/dL
Hematocrit 40.9 %
Platelet count 204 X 10^9/L
Mean corpuscular volume 88 fL
Activated partial thromboplastin time 26.4 s
Prothrombin time 13.7 s
International normalized ratio 1.0
Total bilirubin 0.7 mg/dL
Aspartate aminotransferase (AST) 52 U/L
Alanine aminotransferase (ALT) 43 U/L
Alkaline Phosphatase 75 U/L
Ferritin 1456 ng/mL
Creatine Kinase 511 U/L
HIV antibody Negative
Rapid plasma reagin (RPR) Nonreactive
Hepatitis B Core Antibody Negative
Hepatitis B Surface Antigen Negative
Hepatitis C Antibody Negative
Erythrocyte sedimentation rate (ESR) 3 mm/hr
Anti-nuclear antibody Positive 1:40




Complement C3 107 mg/dL
Complement C4 20.7 mg/dL
Complement CH50 34.6 mg/dL
Angiotensin converting enzyme 73 U/L
CSF Test Result
Red blood cells 43 X 10^6/L




Gram stain No organisms
Bacterial culture No growth
M. Tuberculosis Complex PCR Negative
IgG Index 0.6
Table 1 Initial admission laboratory tests from early June 2012
(Continued)
Oligoclonal bands Multiple bands in CSF and serum
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parietal, right occipital, and left temporal lobes, and the
right cerebellum. The fixed brain weighed 1160 g. Cor-
onal sections of the cerebrum demonstrated multifocal
parenchymal involvement with marked discoloration,
cavitation, softening, and focal hemorrhage. The largest
area extended from the anteriormost aspect of right
frontal lobe to the posterior right occipital lobe and
measured 16.5 × 8 × 4.5 cm. The disease process in-
volved primarily the white matter and relatively spared
the cortex. Similar lesions were found in the left lateral
temporal lobe, right frontal gyrus, and right temporal
lobe (Fig. 3a). In addition, an area of hemorrhage meas-
uring 2.5 × 2 × 2 cm was found in the left basal ganglia,
involving the putamen and white matter of the insula,
and there was expansion of the left hippocampus with
associated cortical thinning and tissue loss in the ento-
rhinal cortex. A right cerebellar infarct was also identi-
fied. The spinal cord showed left lateral column atrophy
spreading throughout the entire spinal column without
evidence of anterior or posterior spinal root atrophy. On
microscopic hematoxylin and eosin sections, the cortical
sections showed profound histiocytic infiltration, peri-
vascular lymphocytosis, and emperipolesis, compatible
with CNS-HLH (Fig. 3b-c). The CD68 immunohisto-
chemical stain demonstrated abundant macrophage
infiltration and emperipolesis (Fig. 3d). Additional neu-
ropathologic microscopic findings included a histiocytic
infiltrate involving the midbrain and pons. The deltoid
and quadriceps skeletal muscle showed diffuse type 2 at-
rophy and mild neurogenic changes, but no lymphohis-
tiocytic infiltrate was present. Findings in other organ
systems included acute and chronic aspiration pneumo-
nia in the right lower lobe and left upper lobe of the
lungs, mild atherosclerosis of the circumflex and left an-
terior descending coronary arteries, mild chronic cystitis
with numerous friable yellow calculi, and testicular atro-
phy. No evidence of systemic HLH was found, including
splenomegaly, hepatitis-like changes, or jaundice.
Fig. 2 Magnetic resonance images from 2012. a-d Axial fluid-attenuated inversion recovery (FLAIR), axial 3D gradient recalled, susceptibility-
weighted image, axial pre-contrast T1, and axial post-contrast T1-weighted images on June 12, 2012. e-h same sequences on June 19, 2012. i-l
same sequences on August 12, 2012
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Discussion
Hemophagocytic lymphohistiocytosis (HLH) is a hyper-
inflammatory syndrome characterized by overactivation
of lymphocytes and macrophages in association with
high levels of cytokines [1–5]. In children, the disease is
relatively uncommon, with an estimated prevalence of
approximately 1/100,000 [13] and incidence of 1.2/
1,000,000 per year [14]. Clinically, it can be associated
with fevers, hepatomegaly, splenomegaly, pancytopenia,
hypertriglyceridemia, hyperferritinemia, and various
neurologic manifestations. The hallmark of disease is the
finding of hemophagocytosis on pathologic examination
of tissues. Treatment options include immunosuppres-
sion and stem cell transplantation [1, 3–5]. The disease
has primary and acquired causes. Primary HLH usually
manifests as a result of defects in genes that encode pro-
teins involved in the exocytosis of cytotoxic granules in
natural killer (NK) cells, which leads to hyperactivation
of the immune system. Genes encoding for perforin,
syntaxin 11, Munc 13-4, and Munc 18-2 proteins have
been implicated [15]. Primary HLH typically manifests
in childhood. Acquired HLH is associated with various
conditions, including infectious and neoplastic etiolo-
gies, which are thought to trigger the syndrome.
Acquired HLH manifests predominantly in adulthood
[1, 3–5]. Most cases of HLH present first with systemic
involvement, [1, 3–5] though cases of central nervous
system HLH (CNS-HLH) have been reported where the
disease presents first with destructive lesions of the brain
and spinal cord with associated meningitis, seizures, or





Russel viper venom test 34.4 s
Anti beta-2 glycoprotein antibodies Negative
Anti cardiolipin antibodies Negative
Serum protein electrophoresis No paraprotein spike
Vitamin B12 580 pg/mL
Lactate dehydrogenase 135 IU/L
Thyroid stimulating hormone 2.4 mIU/L
Anti thyroperoxidase antibody Negative
Anti thyroglobluin antibody Negative
Anti SSA antibody Negative
Anti SSB antibody Negative
Natural killer cell function 63 LUs
Soluble interleukin 2 receptor 713 U/mL
16 s rDNA primer set Negative
28 s rDNA primer set Negative
MELAS A3243G mutation: blood Negative
Urine protein electrophoresis Negative
Kappa/Lambda light chain ratio 0.71
CSF Test Result
Fungal culture No growth
Venereal disease research laboratory test Negative
Galactomannan Negative
Beta-D-glucan Negative
Varicella zoster virus polymerase chain reaction Negative
Whipple polymerase chain reaction Negative
Cytology Heterogeneous lymphocytes
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optic neuritis [6–12]. The majority of such cases occur
in the pediatric population and represent primary CNS-
HLH.
In this case, the pathologic findings at autopsy are
diagnostic of CNS-HLH. In retrospect, the patient’s
presentation of progressive right hand clumsiness with
associated brain lesions ten years earlier likely represents
the earliest manifestation of this disease rather than sub-
acute infarcts as it was deemed at the time. The time
course and radiological similarity with subsequent le-
sions are also compatible with acute-on-chronic mani-
festations of CNS-HLH.
HLH is diagnosed clinically by either 1) having a
proven genetic mutation known to be associated with
HLH or 2) fulfilling 5 out of 8 clinical criteria (fever,
splenomegaly, cytopenias of at least 2 cell lines, hypertri-
glyceridemia and/or hypofibrinogenemia, hyperferritine-
mia, abnormally low NK cell activity, high levels of
soluble IL-2 receptor, and pathologic evidence of hemo-
phagocytosis in tissues) [1, 3, 5, 14]. Our patient had 3
of the 8 clinical criteria: fever, hyperferritinemia, and
hemophagocystosis at the time of brain biopsy. He had a
transient decrease in absolute neutrophil count to 1.25
×109/L and platelets to 119 ×109/L during his initial
hospitalization but these values do not meet the diag-
nostic criteria for cytopenia in HLH. According to the
HLH-94 protocol, therapy includes corticosteroids, eto-
poside, and cyclosporine A, with intrathecal methotrex-
ate for those with progressive neurologic symptoms. In
genetic or refractory cases, a stem cell transplant may be
considered [1, 3, 5, 14, 16]. Our patient was treated em-
pirically with corticosteroids and plasmapheresis for a
presumed autoimmune condition since he did not meet
clinical criteria for HLH.
The frequency of CNS involvement in HLH is unclear,
especially in adults. In one small series CNS involvement
was identified in up to 73 % of patients at the time of diag-
nosis [17]. In another, CNS involvement was present in
30 % of patients who had both HLH and an underlying
autoimmune disorder [18]. In the pediatric population,
neurologic symptoms are variably seen at presentation (be-
tween 13–63 % of patients), and patients may also show
neuroimaging as well as CSF abnormalities [7, 9, 19–21].
Compared to patients who only have systemic symptoms,
neurologic symptoms tend to occur in older patients and
are associated with higher sodium levels, lower ferritin,
lower levels of liver enzymes, and a worse prognosis
[9, 22]. MRI findings include global volume loss, cal-
cifications, enhancing lesions of the gray and white
matter, delayed myelination, and MR spectroscopy
changes (lower N-acetyl aspartate to creatinine ratios)
[23]. CSF involvement may manifest as lymphocytic
Fig. 3 Autopsy neuropathologic findings. a Representative coronal section illustrating destructive lesions involving the bilateral frontal lobes and
right temporal lobe. There was significant destruction of white matter parenchyma with relative preservation of the cortex. b-c Hematoxylin and
eosin sections demonstrating astrogliosis and parenchymal inflammation with numerous macrophages and emperipolesis. The arrow points to a
macrophage containing a red blood cell within its cytoplasm (hemophagocytosis). d CD68 immunohistochemistry highlighting numerous
macrophages with cytoplasmic punched out spaces representing emperipolesis
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pleocytosis and elevated protein [19, 23, 24] and may indi-
cate a worse prognosis with increased mortality [19]. Of
importance to neurologists, isolated neurologic symptoms
as the presenting sign of HLH have been observed in sev-
eral pediatric reports [24–28] but are not particularly
common [7, 9].
It is unknown whether our patient had primary or ac-
quired HLH. While genetic causes are thought to occur
mainly in children and infants, hypomorphic mutations
can result in manifestation of the disease in adulthood
[29]. Furthermore, defects in the gene encoding for the
syntaxin-11 protein have been shown to cause both
HLH and acute myeloid leukemia (AML) [30]. Intri-
guingly, the patient’s daughter has a history of AML,
which raises consideration for a syntaxin-11 mutation
and predisposition to the development of HLH. Alterna-
tively, our patient could have been exposed to an envir-
onmental trigger (such as a virus) that could have
precipitated CNS-HLH. How the therapy with solume-
drol altered the inflammatory milieu prior to the autopsy
is unclear; the lack of significant inflammation in the
liver and other systemic organs could be due to the cor-
ticosteroid therapy. However, since the patient’s labora-
tories were obtained prior to initiation on solumedrol,
the therapy is not a confounder in the lack of clinical/la-
boratory evidence necessary for a diagnosis of systemic
HLH. Furthermore, the autopsy clearly demonstrates
that corticosteroid therapy was not sufficient to prevent
the severe destruction of brain parenchyma. Therefore,
the evidence in this case is most consistent with a case
of CNS-HLH presenting in adulthood.
Conclusions
In conclusion, HLH should be considered in the differ-
ential diagnosis of adults presenting with progressive
brain lesions alone or in association with recurrent fe-
vers, splenomegaly, pancytopenia, hypertriglyceridemia,
hypofibrinogenemia, and/or hyperferritinemia. Further
work is needed to identify diagnostic markers of CNS-
HLH and to determine the role of environmental factors
in the development of HLH.
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